Now Online! CSO RCT Checklist. Common Sense Oncology RCT team has just published in The Lancet Oncology a CHECKLIST to design and report cancer drug RCTs. You know about CONSORT checklist for RCTs but this CSO checklist is specifically for cancer drug RCTs and incorporates items such as

Not long now! Join us this Friday and learn about the latest developments in early phase oncology drug dev across AU and the world! Registrations still open and free for academic/NFP attendees. events.zoom.us/ev/AjHf5uaEMrC…

Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study academic.oup.com/bjs/article-ab…

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study - Annals of Oncology annalsofoncology.org/article/S0923-…

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. aacrjournals.org/cancerres/arti…

1/Do radiologists sound like they are speaking a different language when they talk about MRI? T1 shortening what? T2 prolongation who? Here’s a translation w/an introductory thread to MRI.

Our Medical Director, Dr Charlotte Lemech, will be attending the 2025 ASCO Annual Meeting in Chicago from May 30th to June 2nd. If you're attending ASCO and would like to connect, please reach out, she'd love to meet and share insights on accelerating phase 1 trials in Australia

Woohoo Dr Andrew Parsonson 🤩 this will be good! #ASCO25 And still recruiting various cohorts Scientia Clinical Research (Sydney, Australia)

One page takeaway from #CheckMate8HW study that resulted in Ipi + Nivo FDA Oncology approval on April 8, 2025 for dMMR/MSI-H metastatic colorectal cancer. More data on MSI-H in adj at #ASCO25! #OncTwitter #MedTwitter #gism Nicholas Hornstein

The primary results of #CHALLENGE #RCT will be presented this afternoon in Chicago #ASCO25, you can access them online here now in NEJM nejm.org/doi/full/10.10… linkedin.com/feed/update/ur… #CRCSM #ExerOnc #SuppOnc #SurvOnc CCTG POCOG GI Cancer Institute and AGITG COSA

'Are adjunctive therapies in colon cancer as good as a drug?' Powerful world-first CHALLENGE CO.21 data from #ASCO2025 today showing we can 🚨 now prescribe exercise in addition to standard treatment🚨 Time to rethink cancer $$ ➡️ #ExerciseOncology nejm.org/doi/full/10.10…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

10-year follow up for pembro in MSI-H/dMMR advanced solid tumors 🔎KEYNOTE 16 👉10-yrs OS rate: 46% 👉Rare progression after 2 years 👉We need biomarker to identify (non-) responders 🧐 Great to see 10yr survival data for systemic therapies ESMO - Eur. Oncology

Another money 💰 slide from #asco25 ASCO . Treatment algorithm for HR +/ HER 2 -ve mBC OncoAlert Kate Sears

Pre-typhoon signal 8 night out in #HongKong 🇭🇰 Christina Teng

Indeed a literal whirlwind of experience and knowledge shared this morning! Looking forward to exploring these ideas at home Scientia Clinical Research (Sydney, Australia)

Brilliant example of patience and persistence with a research concept. Injectable radiosensitiser has potential applications in many tumour types (including Brain?🧠? Amd otjer #rarecancers) Johnson & Johnson Innovation

Important data supporting a gentler treatment strategy. Hopefully this leads to fewer women getting chemo toxicity for no survival benefit. 🧠✨️

We are seeing CNS activity with: -multiple ADCs (TDXD, HER3-DXD, TDM1, sacituzumab) -BiTEs (tarlatamab) -bispecifics (ivonescimab) -ICI (ipi/nivo) We need to move to a default of including pts with untreated/progressive brain mets in clinical trials starting in phase 1 !

The NHMRC yesterday announced final allocations for the year. The 2025 success rate for Ideas grants was 10%, Investigator grants 13%, and Clinical Trials 9%. Australia's total spend on healthcare and technology innovation in medicine and biotech from the Medical Research